Related Experiment Video
Updated: Jun 9, 2025

Assays for the Identification of Novel Antivirals against Bluetongue Virus
Published on: October 11, 2013
Structure-based virtual screening and drug repurposing studies indicate potential inhibitors of bovine papillomavirus
Lucas Alexandre Barbosa de Oliveira Santos1, Marcus Vinicius de Aragão Batista1
1Laboratory of Molecular Genetics and Biotechnology, Department of Biology, Center for Biological and Health Sciences, Federal University of Sergipe, São Cristóvão, Sergipe, Brazil.
Abstract:
Bovine papillomavirus type 1 (BPV1) is an oncogenic virus that causes lesions and cancer in infected cattle. Despite being one of the most studied genotypes in the family and occurring in herds worldwide, there are currently no vaccines or drugs for its control. The viral E6 oncoprotein plays a crucial role in infection by this virus, making it a promising target for the development of new therapies. In this regard, we integrated structure-based virtual screening approaches, drug repositioning, and molecular dynamics to identify approved drugs with the potential to inhibit BPV1 E6. Our results reveal that Lumacaftor and MK-3207 are promising candidates for controlling BPV1 infection. The findings of this study may contribute to the development of E6 oncoprotein blockers in an accelerated and cost-effective manner.

